AKBIF yields 276.24% · PFE yields 6.13%● Live data
📍 AKBIF pulled ahead of the other in Year 1
Combined, AKBIF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AKBIF + PFE for your $10,000?
Akebono Brake Industry Co., Ltd. researches, develops, manufactures, and sells brakes, and related components and parts Japan, North America, Europe, and other Asian countries. The company offers disc brake calipers, disc brake pads, disc rotors, drum brake linings, drum brake shoes, wheel cylinders, drum-in-hat brakes, brake drums, sensors, etc. for automobiles; and disc brake calipers, disc brake pads, master cylinders, and others for motorcycles. It also provides brakes for rolling stock, including disc brakes and brake linings for bullet trains, brake linings for regular trains, disc brakes for monorail, brake linings for rolling stock, brake shoes for railroad trains, etc. In addition, the company offers brakes for industrial machinery, such as drum brakes for forklifts, clutch facings for car air conditioner units, brake shoes for elevators, etc., as well as disc brakes for wind turbine generators and rough terrain cranes. Further, it provides sensor products comprising accelerometers, angular rate sensors, and sensor clusters; vehicle behavior detection and wireless portable vibration measurement devices; and inclinometers, concrete filing detectors, light emitting inclination sensors/pockets, and earthquake detectors for long-wave seismic motors. The company was formerly known as Akebono Sekimen Kogyo Co., Ltd. and changed its name to Akebono Brake Industry Co., Ltd. in 1960. Akebono Brake Industry Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.
Full AKBIF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.